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An update to the Cochrane Review on non-surgical interventions for convergence insufficiency by 
Scheiman and colleagues has been recently published [1], providing a summary of current evidence 
for this frequently-encountered clinical condition. This update builds on a previous version of the 
review which was first published by the lead author in 2011 [2]. Key changes include the addition of 
seven new randomised trials, an expanded author team and improved methodology related to the 
search process, reporting of outcome measures, assessment of risk of bias and reporting bias, 
measures of treatment effect, analysis and data synthesis, and evaluation of confidence in the 
evidence (with use of the CINeMA framework and GRADE).  
Treatment of convergence insufficiency is important when the condition leads to symptoms of 
headache, eye strain, double or jumbled vision and reading difficulty. The reported rate of 
convergence insufficiency varies from 2.25%-17.6% [3-5]. Traditionally, treatment has been carried 
out at home after initial assessment and demonstration of the treatment regime in the clinic or 
office environment. The majority of treatment options are non-surgical and typically involve 
convergence training using low-tech near targets such as a pen/pencil or higher-tech computer 
training programmes. Base-in prism glasses are used less frequently [6-8]. Invasive treatment 
options such as extra-ocular muscle surgery or botulinum toxin injection are reserved for refractory 
cases [6,9].  
Whilst there is empirical evidence that non-surgical treatments for convergence insufficiency 
actually work, there is limited evidence as to which approaches might be more effective. This review 
includes randomised trials that have evaluated both home- and office-based non-surgical 
treatments. 
The authors identified a total of 12 randomised trials; six in children (aged 7-18 years) and six in 
adults (aged 15-40 years in five trials and 40+ years in one trial) with 1289 participants overall. The 
trials were conducted over 6 weeks to 6 months. While the review was open to including any non-
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surgical interventions for primary convergence insufficiency, five active interventions were 
evaluated across the 12 included trials:  1) office-based vergence/ accommodative therapy with 
home reinforcement, 2) home-based pencil/ target push-ups, 3) home-based computer vergence/ 
accommodative therapy, 4) office-based vergence/ accommodative therapy alone, 5) prism reading 
glasses. Participants assigned to control groups underwent placebo vergence/ accommodative 
therapy, placebo reading glasses, or other placebo intervention. 
Since children and adults may respond differently to treatments for convergence insufficiency the 
authors separately evaluated trials conducted in children and adults. The six trials in children 
included 968 participants. Composite success rates (normal near point of convergence and positive 
fusional vergence with a-priori improvement criteria) indicated that office-based treatment coupled 
with home-based reinforcement was better than placebo treatment and may be better than home-
based treatment alone, whether using computer training or near target training. There was no 
difference using base-in prism reading glasses versus placebo treatment. The overall certainty of 
evidence was high for all comparisons involving office-based vergence and/or accommodative 
therapy with moderate or low certainty evidence for comparisons between the two home-based 
interventions. Four of six trials rated at low risk of bias.  
The evidence for treatment effectiveness in adults was less clear since composite success rates could 
not be reported for the adult trials. The six trials in adults involved 321 participants and the results 
indicated that office-based treatment was relatively more effective than placebo treatment for 
improving positive fusional vergence and reducing symptom reporting, but interestingly, not more 
effective for improving the near point of convergence. For almost all comparisons in these adult 
trials, the certainty of evidence was low with just one of six trials rated at low risk of bias.  
Overall, there were no reported adverse effects for children or adults. Variable adherence rates 
were reported for home-based treatment whilst adherence rates were excellent for office-based 
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treatment (as would be expected). Cost analysis data and quality of life date were not available for 
any of the included trials.  
 
The overarching conclusion of this Cochrane Review relates to the setting in which treatment is 
performed rather than the treatment modality itself i.e., office-based therapy is more effective than 
home-based therapy. Whilst this conclusion is extremely informative, it is important to note that it is 
likely to reflect the optimal adherence achieved under the direct guidance and supervision of a 
practitioner.  In addition, it is crucial to consider such benefit in the context of the cost and 
convenience of a treatment. Office-based treatments include costs relating to the therapist’s time 
(unless covered by health insurance or national healthcare provider), travel costs to the office, the 
inconvenience of taking time off school and work, each multiplied by numerous sessions. There is a 
cost difference across countries; some with publicly funded healthcare systems (e.g. UK) and others 
requiring health insurance (e.g. USA). Further, for publicly funded healthcare systems, the capacity 
for those systems to offer time-intensive office-based treatment must be weighed against demand 
(e.g. patient load). Where treatment involves computerised programmes, the costs of access to 
computer or tablet devices along with the costs of the treatment programme must also be 
considered. These considerations are vital when aiming to ensure equality of care for our patients 
and cost effectiveness in addition to clinical effectiveness of treatments.  
 
A number of implications for research are, justly, raised. These should inform future trials with 
robust methodologies. The authors have introduced primary outcomes to define treatment success 
which are based on composites of convergence near point, positive fusional vergence and/or 
symptoms. These warrant reporting in future trials. With regard to the treatment itself, it remains 
unclear which specific treatment procedures are better. Are particular combinations of push-up, 
jump and fusional vergence tasks more effective? In addition, in light of cost and equitable access to 
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care, a determination should be made as to whether these treatments are as effective when 
delivered using low-tech, traditional target-based exercises, or if there is an advantage to delivery 
through a computerised programme.  
Future research should also further distinguish between the effects of better adherence and the 
effects of the treatment approach itself when conducting home-based treatment. It is important to 
determine whether a different dose of treatment is needed in a home versus an office environment 
to achieve equivalent outcomes, and also if home-based treatment can be adapted in other ways for 
improved effectiveness. 
Home versus office-based treatment considerations are timely given the current circumstances of 
the COVID-19 pandemic. At a time when office/clinic visits must be minimised, the role of home-
based treatments have received greater attention along with the role of telemedicine. 
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